[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Wu Z, Huang X, Kang F: [The neck treatment of cN0 patients with squamous cell carcinoma of buccal mucosa]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Jun;21(3):194-6
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The neck treatment of cN0 patients with squamous cell carcinoma of buccal mucosa].
  • OBJECTIVE: The purpose of this study was to discuss the principle in neck treatment of cN0 patients with squamous cell carcinoma of buccal mucosa.
  • METHODS: 101 patients of squamous cell carcinoma of buccal mucosa at the stage of cN0, who had hospitalized in West China College of Stomatology, Sichuan University from 1980 to 2000, were investigated retrospectively.
  • All the patients received a comprehensive therapy consisting of surgical procedures combined with chemotherapy and radiotherapy.
  • The combining radical therapy of buccal, mandible and neck was the main surgical method.
  • CONCLUSION: The rate of occult metastasis of squamous cell carcinoma of buccal mucosa is high, and then we should adopt actively selective neck dissection for the cN0 patients of squamous cell carcinoma of buccal mucosa.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lymphatic Metastasis. Mouth Neoplasms / surgery. Neck Dissection
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Mouth Mucosa / surgery. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12898760.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Badakh DK, Grover AH: The efficacy of postoperative radiation therapy in patients with carcinoma of the buccal mucosa and lower alveolus with positive surgical margins. Indian J Cancer; 2005 Jan-Mar;42(1):51-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of postoperative radiation therapy in patients with carcinoma of the buccal mucosa and lower alveolus with positive surgical margins.
  • PURPOSE: A retrospective analysis to determine the efficacy of postoperative radiation therapy, in patients of carcinoma of the buccal mucosa and lower alveolus with pathologically verified positive surgical margins (PSM).
  • MATERIALS AND METHODS: Ninety-four patients were analysed, who underwent surgery plus postoperative radiation therapy.
  • CONCLUSION: To conclude in our study median dose of 60 Gy in PSM patients was not able to improve DFS and showed poor results as compared with NSM patients.
  • There is also evidence from other studies, to suggest that post-operative radiation doses upto 60 Gy may not be sufficient to overcome this poor prognostic factor.
  • In physically fit patients we are trying to administer concomitant chemotherapy along with radiation treatment.
  • [MeSH-major] Mouth Neoplasms / epidemiology. Mouth Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. India / epidemiology. Lymphatic Metastasis. Male. Medical Records. Middle Aged. Mouth Mucosa / pathology. Neoplasm, Residual / radiotherapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805693.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. Liu S, Liao C, Wang D: [The clinical application and evaluation of combined chemotherapy in comprehensive treatment for oral squamous cell carcinoma]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Apr 20;21(2):109-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical application and evaluation of combined chemotherapy in comprehensive treatment for oral squamous cell carcinoma].
  • OBJECTIVE: To study and evaluate the clinical effects of combined preoperative chemotherapy and their relations with multi drug resistance (MDR).
  • METHODS: 102 cases with oral squamous cell carcinoma(OSCC) were included in the study (63 males and 39 females, aged 22 to 67 years).
  • Among the subjects there were 57 cases with cancer of tongue and 45 cases with cancer of buccal mucosa.
  • All cases accepted PYM + 5-Fu + DDP combined chemotherapy pre-operatively.
  • After the chemotherapy, radical surgery were performed within 2 weeks.
  • The diagnosis of all cases were proved as OSCC by biopsy.
  • RESULTS: Total effective rate of the combined chemotherapy was 82.4%.
  • CONCLUSION: The combined chemotherapy of PYM + 5-Fu + DDP is effective in using as one of comprehensive treatment for OSCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / analogs & derivatives. Carcinoma, Squamous Cell / therapy. Mouth Neoplasms / therapy. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12838692.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 77108-50-0 / zhengguangmycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Wang HM, Ng SH, Wang CH, Liaw CT, Chen JS, Yang TS, Chen IH: Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa. Anticancer Drugs; 2001 Apr;12(4):331-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
  • From July 1994 to December 1996, 41 patients with previously untreated, advanced bulky squamous cell carcinoma arising from the buccal mucosa (BSCC) were enrolled.
  • Patients were initially scheduled to receive intra-arterial (i.a.) chemotherapy, followed by i.v. chemotherapy and regional therapy.
  • The i.a. chemotherapy catheter was properly placed by external carotid artery angiography via the femoral artery.
  • The i.a. chemotherapy consisted of cisplatin (P) 100 mg/m(2) day 1 plus 5-fluorouracil (F) 1000 mg/m(2) day 1-4, and the i.v. chemotherapy consisted of PF (10 patients) or PF plus methotrexate 200 mg/m(2) day 15 and 22 (31 patients).
  • All chemotherapy regimens were administered at 4-week intervals.
  • The response rate of i.a. plus i.v. chemotherapy for the primary site was 85% (35 of 41) with 29% complete remission (CR) (12 of 41).
  • Major toxicity from i.a. chemotherapy of WHO grade > or = 3 included: mucositis of infusion area (76%), hemialopecia (56%) and leukopenia (5%).
  • Three neurologic complications of i.a. chemotherapy including one hemiparesis occurred.
  • The median follow-up time was 47 months (range 36-66 months), and the overall survival and disease-free survival were both 34% (14 of 41).
  • Four patients were cured with chemotherapy alone and eight patients (19.5%) were cured without surgical intervention.
  • Using i.a. chemotherapy as a cytoreductive therapy followed by subsequent i.v. chemotherapy produces a high response rate and an encouraging degree of complete response rate in advanced bulky BSCC.
  • However, toxicity management and catheter placement will need to be improved in order to better define the role of this therapy in advanced BSCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Eruptions / etiology. Dyspnea / chemically induced. Dyspnea / drug therapy. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial / methods. Infusions, Intravenous / methods. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Middle Aged. Mouth Mucosa. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Stomatitis / chemically induced. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11335789.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Ogiuchi Y, Maruoka Y, Ando T, Kobayashi M, Ogiuchi H: Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma. Acta Histochem Cytochem; 2008 Jun 27;41(3):39-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
  • We conducted a clinicopathologic study on protein and mRNA levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and orotate phosphoribosyl transferase (OPRT) using biopsy tissue specimens before treatment.
  • We studied the mRNA and protein expression as effect predictive factors in chemotherapy.
  • The subjects consisted of 20 cases of untreated oral squamous cell carcinoma who had undergone chemotherapy with TS-1 (16 males and 4 females, tongue in 8 cases, upper gingiva in 3 cases, lower gingiva in 3 cases, buccal mucosa in 5 cases and floor of the mouth in 1 case).
  • Furthermore, regarding males who were less than 70 years of age, stage I and II, well differentiated type and tongue, TS mRNA expression of the responders were lower than that for the nonresponders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1486-92 [14562021.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1417-23 [16685374.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):717-23 [12464897.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):42-9 [10618604.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2371-6 [9796967.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(12):1295-302 [17101591.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Mar;35(3):265-9 [16257511.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):884-9 [16189518.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):276-82 [15743690.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):336-44 [15737843.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1245-50 [15354215.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4116-24 [14519634.001]
  • [Cites] Oral Oncol. 2006 Oct;42(9):880-7 [16757204.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):967-73 [15316940.001]
  • (PMID = 18636111.001).
  • [ISSN] 0044-5991
  • [Journal-full-title] Acta histochemica et cytochemica
  • [ISO-abbreviation] Acta Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2447914
  • [Keywords] NOTNLM ; oral cancer / orotate phosphoribosyl transferase / thymidine phosphorylase / thymidylate synthase
  •  go-up   go-down


6. Smith Y, Hadway P, Ahmed S, Perry MJ, Corbishley CM, Watkin NA: Penile-preserving surgery for male distal urethral carcinoma. BJU Int; 2007 Jul;100(1):82-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile-preserving surgery for male distal urethral carcinoma.
  • OBJECTIVE: To evaluate medium-term outcome data from patients with distal urethral cancers treated with penile-preserving surgery.
  • PATIENTS AND METHODS: We analysed prospectively 18 consecutive men referred for the management of urethral carcinoma.
  • RESULTS: All 18 patients were suitable for penile-preserving surgery; the procedures were: three hypospadias formation with or without topical chemotherapy; four buccal mucosa urethroplasty; three glansectomy and reconstruction; six glansectomy, distal corporectomy, reconstruction and hypospadias formation; two urethrectomy with or with no excision of adjacent tunica albuginea.
  • CONCLUSION: Medium-term data show that penile-preserving surgery is a feasible treatment for men with distal urethral carcinoma, providing excellent local control without prejudicing survival; a longer follow-up is needed.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Penis / surgery. Urethral Neoplasms / surgery. Urologic Surgical Procedures, Male / standards
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Feasibility Studies. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488307.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Prakash O, Varghese BT, Mathews A, Nayak N, Ramchandran K, Pandey M: Radiation induced osteogenic sarcoma of the maxilla. World J Surg Oncol; 2005 Jul 21;3:49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Radiation induced sarcoma arise as a long term complication of radiation treatment for other benign or malignant conditions.
  • CASE PRESENTATION: Here we report a case of radiation induced sarcoma in a patient treated for squamous cell carcinoma of buccal mucosa with radiation who developed osteosarcoma of maxillary bone after six years.
  • CONCLUSION: What should be the best treatment of radiation induced sarcoma is still debatable; however, surgery offers the best chance of cure.
  • Role of reradiation and adjuvant chemotherapy needs to be further evaluated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 1999 Jul;21(4):346-54 [10376755.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):598-605 [11169944.001]
  • [Cites] J Oral Maxillofac Surg. 2001 Apr;59(4):415-20 [11291700.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Apr;91(4):445-51 [11312461.001]
  • [Cites] Curr Treat Options Oncol. 2000 Aug;1(3):258-61 [12057168.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1495-503 [12237918.001]
  • [Cites] Head Neck. 1994 May-Jun;16(3):246-52 [8026955.001]
  • [Cites] Radiology. 1978 Nov;129(2):501-8 [279941.001]
  • [Cites] Cancer. 1967 Mar;20(3):377-91 [5228026.001]
  • [Cites] Am Surg. 1970 Aug;36(8):463-71 [5271158.001]
  • [Cites] J Oral Surg. 1971 Feb;29(2):126-9 [5279098.001]
  • [Cites] Cancer. 1971 Nov;28(5):1087-99 [5288429.001]
  • [Cites] Cancer. 1983 Jun 15;51(12):2311-6 [6573939.001]
  • [Cites] Cancer. 1990 Nov 1;66(9):1924-6 [2224788.001]
  • (PMID = 16042767.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1199630
  •  go-up   go-down


8. Jenwitheesuk K, Surakunprapha P, Chowchuen B, Tangvoraphongchai V, Pesee M, Krusun S, Supaadirek C: Results of multidisciplinary therapy of squamous cell carcinoma of the buccal mucosa at Srinagarind Hospital, Thailand. J Med Assoc Thai; 2010 Nov;93(11):1262-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of multidisciplinary therapy of squamous cell carcinoma of the buccal mucosa at Srinagarind Hospital, Thailand.
  • OBJECTIVE: Review the clinical presentation and treatment of buccal carcinoma and compare it to the results of treatment as per survival rate.
  • MATERIAL AND METHOD: The authors reviewed the medical records of newly diagnosed seen between 1995 and 2005 at the Division of Plastic Surgery and the Department of Radiotherapy, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University Patients previously treated elsewhere or those whose lesions secondarily involved the buccal mucosa were excluded.
  • RESULTS: The authors reviewed the medical records of 107 buccal carcinoma patients (94 females and 13 males) averaging 67 years of age.
  • A combined modality treatment (surgery and radiation or chemotherapy) was used to treat the advanced stage (III and IV) patients.
  • The rate of incomplete therapy was high (47.78%).
  • In the group that completed the protocol (i.e., neoadjuvant, surgery, and post operative radiation), there were five patients for whom the 5-year survival seemed higher than the patients who followed the standard treatment of surgery and post-operative radiation but it was not statistically significant.
  • CONCLUSION: The treatment of buccal carcinoma requires a multidisciplinary team approach because most of the patients are elderly and present with an advanced stage.
  • If treatment continues through to completion of the protocol, the survival rate would increase.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Mucosa / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Hospitals, Teaching. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Thailand

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21114204.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


9. Nishimura N, Matsushita Y, Takaoka K, Hashitani S, Noguchi K, Urade M: [Treatment of hypercalcemia of malignancy with pamidronate in a patient with advanced recurrent oral cancer]. Gan To Kagaku Ryoho; 2002 Dec;29(13):2537-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of hypercalcemia of malignancy with pamidronate in a patient with advanced recurrent oral cancer].
  • Treatment of hypercalcemia of malignancy with pamidronate in a patient with advanced recurrent oral cancer is reported herein.
  • The patient was a 36-year-old man who had neck lymph node metastases due to recurrence of squamous cell carcinoma of the buccal mucosa and complained of cloudiness of consciousness due to hypercalcemia.
  • Although treatment of hypercalcemia with pamidronate is palliative, it is effective against the deterioration of quality of life.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Diphosphonates / therapeutic use. Hypercalcemia / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Consciousness Disorders / etiology. Drug Administration Schedule. Humans. Lymphatic Metastasis. Male. Quality of Life

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506478.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; OYY3447OMC / pamidronate
  •  go-up   go-down


10. Tsurumaru D, Kuroiwa T, Yabuuchi H, Hirata H, Higaki Y, Tomita K: Efficacy of intra-arterial infusion chemotherapy for head and neck cancers using coaxial catheter technique: initial experience. Cardiovasc Intervent Radiol; 2007 Mar-Apr;30(2):207-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of intra-arterial infusion chemotherapy for head and neck cancers using coaxial catheter technique: initial experience.
  • The aim of this study was to evaluate the efficacy of intra-arterial infusion chemotherapy for head and neck cancers using a coaxial catheter technique: the superficial temporal artery (STA)-coaxial catheter method.
  • Thirty-one patients (21 males and 10 females; 37-83 years of age) with squamous cell carcinoma of the head and neck (maxilla, 2; epipharynx, 4; mesopharynx, 8; oral floor, 4; tongue, 10; lower gingiva, 1; buccal mucosa, 2) were treated by intra-arterial infusion chemotherapy.
  • Four patients were excluded from the tumor-response evaluation because of a previous operation or impossibility of treatment due to catheter trouble.
  • External radiotherapy was administered during intra-arterial chemotherapy at a total dose of 21-70.5 Gy.
  • Injury and dislocation of the microcatheter occurred 10 times in 7 patients.
  • Catheter infection was observed three times in each of two patients, and catheter occlusion and vasculitis occurred in two patients.
  • Intra-arterial infusion chemotherapy via the STA-coaxial catheter method could have potential as a favorable treatment for head and neck tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Catheterization, Peripheral / methods. Head and Neck Neoplasms / drug therapy. Infusions, Intra-Arterial
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Brachytherapy. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Temporal Arteries. Treatment Outcome. Tumor Burden / drug effects. Tumor Burden / radiation effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216381.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


11. Grau JJ, Domingo J, Blanch JL, Verger E, Castro V, Nadal A, Alós L, Estapé J: Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology; 2002;63(4):338-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study.
  • OBJECTIVES: To determine outcomes in local-regional control and overall survival in patients with squamous locally advanced cancer of the oral cavity, based on intention-to-treat with neoadjuvant chemotherapy followed by surgery or radiation therapy.
  • All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue).
  • Chemotherapy was based on cisplatin 120 mg/m(2) i.v. day 1 plus bleomycin 20 mg/m(2) days 1-5 in continuous i.v. perfusion or plus 5-fluorouracil 1,000 mg/m(2) days 1-5 in continuous i.v. perfusion.
  • Definitive surgery (n = 73; plus adjuvant radiation therapy) or definitive radiation therapy (n = 131) was performed.
  • RESULTS: One hundred thirty-five out of 204 (66%) patients were chemotherapy responders, 16% complete and 50% partial.
  • One hundred ninety-four patients (95%) completed 2 courses of chemotherapy.
  • After neoadjuvant chemotherapy, 34 out of 46 patients considered inoperable initially (74%) obtained a disease-free status with surgery.
  • Eighty-three percent of surgical patients obtained a disease-free status (initial tumor control) versus 72% of radiation therapy patients.
  • A better prognosis was observed in stage III over IV (p = 0.02); primary tumor in the retromolar trigone, palate or buccal mucosa over tongue, tonsil or floor of the mouth (p = 0.0085); negative cervical nodes over positive (p = 0.0186); responders to chemotherapy over nonresponders (p = 0.0003); and adjuvant postsurgical radiation therapy (p = 0.0013).
  • CONCLUSIONS: In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12417788.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Yamamoto K, Obara S, Mishima K, Nakamura H, Yoshimura Y: [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1]. Gan To Kagaku Ryoho; 2004 Apr;31(4):635-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1].
  • We report a case of advanced squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to oral chemotherapy with TS-1.
  • We carried out chemotherapy with TS-1 50 mg/day, without surgical treatment.
  • Adverse drug reactions, including vomiting, leukopenia and thrombopenia, forced a stop of the administration of TS-1.
  • Although she finally died of in senescence 2 months from the cease of administration, there was no recurrence of the cancer at the time.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Gingival Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Female. Humans. Leukopenia / chemically induced. Mouth Mucosa / pathology. Neoplasm Invasiveness. Remission Induction. Thrombocytopenia / chemically induced. Vomiting, Anticipatory / etiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114716.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


13. Giannola LI, De Caro V, Giandalia G, Siragusa MG, Paderni C, Campisi G, Florena AM: 5-Fluorouracil buccal tablets for locoregional chemotherapy of oral squamous cell carcinoma: formulation, drug release and histological effects on reconstituted human oral epithelium and porcine buccal mucosa. Curr Drug Deliv; 2010 Apr;7(2):109-17
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil buccal tablets for locoregional chemotherapy of oral squamous cell carcinoma: formulation, drug release and histological effects on reconstituted human oral epithelium and porcine buccal mucosa.
  • 5-Fluorouracil (5-FU) is currently used for treatment of oral squamous cell carcinoma (OSCC).
  • 5-FU is given by i.v. although the systemic administration is associated with severe toxic effects and no topical formulations of 5-FU for buccal drug delivery have been reported.
  • In this study we would report the development of buccal tablets suitable for direct application of low-doses of 5-FU on cancer lesions.
  • Preliminarily, the limited tendency of 5-FU to cross the buccal tissue was established using reconstituted human oral epithelium (RHOE, in vitro) and porcine buccal mucosa (ex vivo) as mucosal models.
  • Matrix buccal tablets, were designed for 5-FU local delivery, developed and prepared.
  • Release tests showed a highly reproducible Higuchian drug discharge.
  • After tablet administration on buccal tissue specimens, the occurrence of histo-morphological effects of 5-FU was highlighted.
  • Apoptotic events were registered in all samples treated while only negligible amounts of 5-FU permeated the buccal membrane and reached the simulated plasma.
  • The results suggest that loaded matrix tablets containing 5% of 5-FU could be a useful means in topical treatment of OSCC.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Chemistry, Pharmaceutical / methods. Fluorouracil / administration & dosage. Mouth Neoplasms / drug therapy. Tablets / administration & dosage
  • [MeSH-minor] Administration, Buccal. Animals. Apoptosis / drug effects. Drug Compounding / methods. Drug Delivery Systems / methods. Humans. Mouth Mucosa / anatomy & histology. Mouth Mucosa / drug effects. Permeability. Swine. Tissue Culture Techniques

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20158481.001).
  • [ISSN] 1875-5704
  • [Journal-full-title] Current drug delivery
  • [ISO-abbreviation] Curr Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Tablets; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Rousseau A, Taberne R, Siberchicot F, Fricain JC, Zwetyenga N: [Cancer of the cheek in a patient under etanercept]. Rev Stomatol Chir Maxillofac; 2009 Nov;110(5):306-8
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the cheek in a patient under etanercept].
  • However, no case of association with oral carcinoma had ever been described.
  • The aim of this study was to report a case of carcinoma of the cheek mucosa in a patient treated with etanercept for rheumatoid polyarthritis.
  • OBSERVATION: An 82-year-old female patient, non smoker, consulted for a tumour of the oral cavity.
  • History revealed that this lesion had appeared soon after the initiation of etanercept treatment for severe and resistant rheumatoid polyarthritis.
  • Clinical observation revealed a tumour of the right cheek mucosa 5 by 3 cm.
  • The histological examination of the surgical piece revealed a micro-infiltrative and non-invasive orthoplastic epidermoid carcinoma.
  • DISCUSSION: The possible development of an oral cavity carcinoma should be taken into account when following a patient under TNF-alpha inhibitor treatment.
  • Anti-TNF treatment has improved the management of patients with severe chronic inflammatory diseases.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Carcinoma, Squamous Cell / chemically induced. Immunoglobulin G / adverse effects. Mouth Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836037.001).
  • [ISSN] 1776-257X
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; OP401G7OJC / Etanercept
  •  go-up   go-down


15. Mukasa Y, Ichiyasu H, Akaike K, Okamoto S, Komohara Y, Kohrogi H: [Autopsy case of pulmonary zygomycosis and pneumocystis pneumonia in a patient with interstitial pneumonia treated by corticosteroid therapy]. Nihon Kokyuki Gakkai Zasshi; 2010 Nov;48(11):847-54
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of pulmonary zygomycosis and pneumocystis pneumonia in a patient with interstitial pneumonia treated by corticosteroid therapy].
  • We report a 75-year-old man with pneumoconiosis, interstitial pneumonia and diabetes mellitus, who had carcinoma of the buccal mucosa.
  • After resection of the carcinoma, he was given corticosteroids for the deterioration of interstitial pneumonia, but 38 days after initiating steroid therapy, he was admitted to our hospital with severe hypoxemia and multiple cavitary lesions superimposed on ground-glass attenuation in both lung fields.
  • At 20 days after these treatments he developed bloody sputum, and Cunninghamella bertholletiae was isolated from the BAL fluid obtained at admission.
  • A diagnosis of pulmonary zygomycosis was finally established.
  • Amphotericin B therapy was started, and the dose was increased thereafter.
  • Despite intensive treatment he died 18 days later.
  • Histological examination of lung tissue obtained at autopsy showed invasive growth of zygomycetes in the necrotic tissue and the cavity wall.
  • To the best of our knowledge, this is the first report of concurrent Cunninghamella bertholletiae and Pneumocystis jirovecii infection during steroid therapy for interstitial pneumonia.
  • [MeSH-major] Autopsy. Cunninghamella. Lung / pathology. Lung Diseases, Fungal / complications. Lung Diseases, Fungal / pathology. Lung Diseases, Interstitial / complications. Lung Diseases, Interstitial / drug therapy. Methylprednisolone / administration & dosage. Mucormycosis / complications. Mucormycosis / pathology. Pneumocystis jirovecii. Pneumonia, Pneumocystis / complications. Pneumonia, Pneumocystis / pathology
  • [MeSH-minor] Aged. Antifungal Agents / administration & dosage. Diabetes Complications. Drug Therapy, Combination. Fatal Outcome. Humans. Immunocompromised Host. Male. Mouth Mucosa. Mouth Neoplasms / complications. Pneumoconiosis / complications. Pulmonary Aspergillosis / complications

  • Genetic Alliance. consumer health - Zygomycosis.
  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141065.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


16. Vorob'ev IuI, Garbuzov MM, Retinskaia II, Popov NV: [The clinical picture, diagnosis and radiation treatment principles in cancer of the buccal mucosa]. Stomatologiia (Mosk); 2000;79(1):36-8
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical picture, diagnosis and radiation treatment principles in cancer of the buccal mucosa].
  • Diagnosis and treatment of 228 patients with cancer of the buccal mucosa is analyzed.
  • Squamous-cell carcinomas with hornification predominated: 217 cases (95%).
  • For cosmetic reasons, radiotherapy (oral x-ray therapy, interstitial method, long-distance gamma beam therapy) was the method of choice.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma / diagnosis. Carcinoma / radiotherapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / diagnosis. Mouth Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cheek. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Mouth Mucosa. Neoplasm Staging. Radiotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10693346.001).
  • [ISSN] 0039-1735
  • [Journal-full-title] Stomatologii︠a︡
  • [ISO-abbreviation] Stomatologiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] RUSSIA
  •  go-up   go-down


17. Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, Tatematsu N: [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment]. Gan To Kagaku Ryoho; 2000 Jan;27(1):65-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment].
  • A combination of radiotherapy and chemotherapy is a usual treatment method for malignant head and neck tumors, however chemoradiotherapy is associated with hematopoietic impairment and serious stomatitis in patients.
  • The clinical effects and evaluation of hematopoietic activity (e.g., leukocyte count) and the degree of stomatitis under adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer were investigated for preoperative cancer therapy.
  • In order to evaluate the clinical effects of Ancer 20 injection with regard to hematopoietic activity and the degree of stomatitis, a clinical study was performed for 18 patients with oral cancer in our department.
  • The 18 patients, who had oral squamous cell carcinomas (5 of the tongue, 4 of the mandibular gingiva, 3 of the maxillary gingiva, 1 of the floor of the mouth, 3 of the buccal mucosa, and 2 others), were treated with this combination of adjuvant therapy with Ancer 20 injection, from March, 1991 to March, 1997.
  • They were injected with Ancer 20 (twice a week, 40 micrograms) during the cancer treatment period.
  • We investigated hematopoietic activity, (e.g., leukocyte and platelet counts) and the degree of stomatitis periodically, before and after the combined radiotherapy and chemotherapy treatment period.
  • These results suggest that Ancer 20 injection may generally improve various dysfunctions due to hematopoietic impairment by radiotherapy combined with chemotherapy, and improve immunological factors.
  • We conclude that Ancer 20 injection is a useful adjuvant treatment for oral cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Leukopenia / prevention & control. Mouth Neoplasms / drug therapy. Radiation-Protective Agents / administration & dosage. Stomatitis / prevention & control
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Leukocyte Count. Lipids / administration & dosage. Mannans / administration & dosage. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10660735.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lipids; 0 / Mannans; 0 / Radiation-Protective Agents; 0 / specific substance maruyama
  •  go-up   go-down


18. Osano H, Watanabe S, Numao A: [A case report of radiation-induced cancer of the buccal mucosa, effectively treated with CF therapy]. Gan To Kagaku Ryoho; 2001 Feb;28(2):257-60
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of radiation-induced cancer of the buccal mucosa, effectively treated with CF therapy].
  • We report favorable effect of combination chemotherapy with CDDP and 5-FU for a case of radiation-induced cancer of the left buccal mucosal membrane.
  • A 71-year-old man underwent external-beam radiotherapy for a squamous cell carcinoma of the tongue.
  • He developed left buccal mucosal cancer 13 years after the start of this radiotherapy.
  • One course of the therapeutic regimen consisted of CDDP 70 mg/m2/day drip infusion for 2 hours (day 1) and 5-FU 700 mg/m2/day drip infusion for 120 hours (days 1-5).
  • A partial response was achieved after 1 course, after which additional treatment with the same regimen was made with favorable effect.
  • Four years after the treatment, 2 courses of the same chemotherapy were performed because of a recurrence of radiation-induced cancer, with a complete response.
  • A histopathological examination of the lesion showed no cancer tissue.
  • The patient was alive and cancer free 4 years after the treatment, and has been followed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mouth Mucosa. Mouth Neoplasms / drug therapy. Mouth Neoplasms / etiology. Neoplasms, Radiation-Induced / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Tongue Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Radiation induced cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242658.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC: Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg; 2003 Jul;61(7):751-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival.
  • PURPOSE: The study goal was to determine which clinical features correlated with 5-year survival in patients surgically treated for oral squamous cell carcinoma (OSCC) in Taiwan.
  • PATIENTS AND METHODS: The records of 378 OSCC patients surgically treated with or without chemotherapy and radiotherapy were reviewed retrospectively.
  • Tumors occurred mainly at the buccal mucosa (BM) (100 of 378, 26.5%), gingiva (105 of 378, 27.8%), and tongue (103 of 378, 27.2%).
  • Neck nodal metastasis occurred frequently at the floor of the mouth (in >60% of cases), followed by the gingiva (45.7%), buccal mucosa (34%), and tongue (20.4%), whereas early distant metastasis was rare (5.3%).
  • CONCLUSIONS: Our data suggest that early treatment is the key to increasing the survival of OSCC patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Areca / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Linear Models. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Sex Factors. Smoking / adverse effects. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856245.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Gomez DR, Zhung JE, Gomez J, Chan K, Wu AJ, Wolden SL, Pfister DG, Shaha A, Shah JP, Kraus DH, Wong RJ, Lee NY: Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys; 2009 Mar 15;73(4):1096-103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.
  • PURPOSE: To present our single-institution experience of intensity-modulated radiotherapy (IMRT) for oral cavity cancer.
  • METHODS AND MATERIALS: Between September 2000 and December 2006, 35 patients with histologically confirmed squamous cell carcinoma of the oral cavity underwent surgery followed by postoperative IMRT.
  • The sites included were buccal mucosa in 8, oral tongue in 11, floor of the mouth in 9, gingiva in 4, hard palate in 2, and retromolar trigone in 1.
  • Ten patients (29%) also received concurrent postoperative chemotherapy with IMRT.
  • The median prescribed radiation dose was 60 Gy.
  • Treatment failure occurred in 11 cases as follows: local in 4, regional in 2, and distant metastases in 5.
  • CONCLUSION: IMRT as an adjuvant treatment after surgical resection for oral cavity tumors is feasible and effective, with promising results and acceptable toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707827.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Elad S, Levitt M, M Y S: [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment]. Refuat Hapeh Vehashinayim (1993); 2008 Nov;25(4):19-27, 72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
  • Graft versus host disease (GVHD) is an alloimmune inflammatory process, which results from a donor-origin cellular response against host tissues.
  • The chronic syndrome of GVHD (cGVHD) occurs in approximately 50% of patients post hematopoietic stem cell transplantation (HSCT) and remains the leading cause of non-malignant mortality.
  • Oral cavity is one of the most frequent sites involved in cGVHD, possibly only second to skin.
  • The oral tissues targeted by cGVHD are the mucosae, the salivary glands, the musculoskeletal apparatus and the periodontal structures.
  • In addition to impaired oral functions, cGVHD may lead to secondary malignancies in the form of solid cancers, particularly squamous cell carcinomas of the oral cavity.
  • Moreover, administration of systemic azathioprine, a commonly used immunosuppressive drug in cGVHD patients, may significantly increase the incidence of tumors of oral cavity.
  • Scoring of oral GVHD was first addressed by NIH only in 2005.
  • The NIH consensus paper referred to standard criteria for diagnosis, classification, and response to treatment.
  • Management of oral cGVHD is compromised of preventive protocols and when cGVHD is developed, systemic and topical treatment.
  • Because the majority of patients with oral cGVHD will develop the extensive form of the disease, they will be treated systemically.
  • Systemic treatment is based on steroids and immunosuppressants, and, thus, increases the frequency of opportunistic infections.
  • Only a few well-designed controlled trials using systemic treatments for cGVHD assessed oral outcomes.
  • When the oral mucosa is the only site resistant to high doses of systemic corticosteroids or when GVHD is manifested only in the oral mucosa, the treatment approach should be topical therapy.
  • Topical steroid preparations are the mainstay of local treatment.
  • Budesonide is a novel steroid preparation that is being developed in the recent years for cGVHD.
  • Its high topical anti-inflammatory activity together with low systemic bioavailability may provide enhanced treatment effects for local oral disease while sparing the host immunity.
  • Second line of topical therapy includes pharmacologic immunosuppressants and phototherapy, combined with palliative treatment.
  • This article aims at presenting the novel information about the clinical presentation, scoring scales, long term complications and treatment for mucosal cGVHD.
  • [MeSH-major] Graft vs Host Disease / diagnosis. Mouth Diseases / diagnosis
  • [MeSH-minor] Administration, Buccal. Adrenal Cortex Hormones / therapeutic use. Carcinoma, Squamous Cell / diagnosis. Chronic Disease. Glucocorticoids / therapeutic use. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Immunosuppressive Agents / therapeutic use. Lichenoid Eruptions / diagnosis. Mouth Mucosa / pathology. Mouth Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Oral Ulcer / diagnosis. Phototherapy

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263864.001).
  • [ISSN] 0792-9935
  • [Journal-full-title] Refuʼat ha-peh ṿeha-shinayim (1993)
  • [ISO-abbreviation] Refuat Hapeh Vehashinayim (1993)
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Glucocorticoids; 0 / Immunosuppressive Agents
  •  go-up   go-down


22. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T, Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl; 2002;(547):25-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment effects in patients with squamous cell carcinoma of the oral cavity.
  • A total of 221 patients (155 males, 66 females; stage I, n = 55: stage II, n = 58; stage III, n = 57; stage IV, n = 51) with squamous cell carcinoma of the oral cavity were studied.
  • Tumor localization was as follows: cancer of the tongue, n = 161; cancer of the oral floor, n = 28; cancer of the hard palate, n = 12; cancer of the buccal mucosa, n = 11; and cancer of the gingiva, n = 9.
  • In order to compare the effect of different treatments, three major treatment groups were defined, namely a surgery group, a radiotherapy group and a combination treatment group.
  • The 5-year cumulative survival rate was highest for oral floor cancer (80%).
  • No significant difference in regional control rates was observed between the treatment groups.
  • [MeSH-major] Antineoplastic Protocols. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Mouth / drug effects. Mouth / radiation effects. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Severity of Illness Index. Survival Rate


23. Harada K, Sato M, Ueyama Y, Nagayama M, Hamakawa H, Nagahata S, Yoshimura Y, Osaki T, Ryoke K, Oral Cancer Study Group of Chugoku-Shikoku: Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs; 2008 Jan;19(1):85-90
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma.
  • The aim of this study was to investigate the efficacy and safety of an oral fluoropyrimidine anticancer agent, S-1, in patients with oral squamous cell carcinoma.
  • Patients with pathologically confirmed squamous cell carcinoma and at least one measurable lesion were enrolled.
  • Oral administration of S-1 (40 mg/m2 twice daily) for 28 days was followed by a 14-day rest period.
  • The sites of the primary tumor were the gingiva (n=18), the tongue (n=12), the palate (n=5), the oral floor (n=4), the buccal mucosa (n=1), and the labial mucosa (n=1).
  • A median of two cycles of treatment (range, 1-5) was administered.
  • S-1 exhibits definite antitumor activity in patients with oral squamous cell carcinoma and is well tolerated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Combinations. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043133.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


24. Gkoulioni V, Eleftheriadou A, Yiotakis I, Ferekidou E, Chrisovergis A, Lazaris ACh, Kandiloros D: The efficacy of imiquimod on dysplastic lesions of the oral mucosa: an experimental model. Anticancer Res; 2010 Jul;30(7):2891-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of imiquimod on dysplastic lesions of the oral mucosa: an experimental model.
  • AIM: To study the potent efficacy of the immunomodulatory agent imiquimod when applied on dysplastic lesions of the oral mucosa.
  • MATERIALS AND METHODS: Carcinogen (DMBA) was applied to the mucosa of the left buccal pouch of 26 male Wistar rats for 8 weeks, until dysplastic lesions were observed and histologically diagnosed.
  • Biopsies were taken before and after treatment.
  • In one case, a well-differentiated squamous cell carcinoma was converted to a papilloma-like squamous neoplasm with a benign morphology.
  • CONCLUSION: Our results indicate that imiquimod may be effective in treatment of precancerous lesions of the oral mucosa and thus inhibit the progress of carcinogenesis.
  • [MeSH-major] Aminoquinolines / pharmacology. Mouth Neoplasms / prevention & control. Precancerous Conditions / drug therapy
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Antineoplastic Agents / pharmacology. Carcinogens. Carcinoma, Squamous Cell / chemically induced. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Male. Mouth Mucosa / drug effects. Mouth Mucosa / pathology. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683029.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 99011-02-6 / imiquimod
  •  go-up   go-down


25. Misra S, Chaturvedi A, Misra NC: Management of gingivobuccal complex cancer. Ann R Coll Surg Engl; 2008 Oct;90(7):546-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Squamous cell carcinoma of the oral cavity ranks as the 12th most common cancer in the world and the 8th most frequent in males.
  • The search terms carcinoma oral cavity, and cancer oral cavity, buccal mucosa, gingiva, gingivobuccal complex, and alveolus cancer/carcinoma were used.
  • RESULTS: Treatment of gingivobuccal complex cancer is primarily surgical.
  • Radical neck dissection, or its modification, is the standard treatment for the node-positive neck.
  • Supraomohyoid neck dissection is the accepted treatment for the node-negative neck.
  • Radiotherapy is usually not the preferred modality of treatment for early gingivobuccal complex cancer.
  • It is used either as postoperative adjuvant treatment or as definitive treatment for advanced cancer with or without chemotherapy.
  • Chemotherapy has been used as neo-adjuvant, adjuvant or palliative treatment.
  • Advanced cancers constitute a major proportion of patients presenting for treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Gingival Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Neck Dissection / methods. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] JAMA. 2007 Jul 4;298(1):70-82 [17609492.001]
  • [Cites] Br J Oral Maxillofac Surg. 2001 Dec;39(6):411-8 [11735134.001]
  • [Cites] Head Neck. 2002 Mar;24(3):282-9 [11891961.001]
  • [Cites] Lancet Oncol. 2000 Sep;1(1):37-42 [11905687.001]
  • [Cites] Head Neck. 1995 May-Jun;17(3):199-203 [7782204.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(3):143-5 [7662347.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):119-23 [7558808.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jun;122(6):634-8 [8639295.001]
  • [Cites] Eur J Surg Oncol. 1996 Oct;22(5):502-4 [8903493.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):650-3 [8988669.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):654-7 [8988670.001]
  • [Cites] Am J Surg. 1998 Nov;176(5):422-7 [9874426.001]
  • [Cites] Head Neck. 1999 Jan;21(1):39-42 [9890349.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Head Neck. 1999 Mar;21(2):104-10 [10091977.001]
  • [Cites] Br J Oral Maxillofac Surg. 1999 Jun;37(3):205-9 [10454028.001]
  • [Cites] Am J Surg. 1999 Jul;178(1):73-7 [10456709.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):778-85 [15599855.001]
  • [Cites] Lancet Oncol. 2001 May;2(5):261-9 [11905780.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 May;128(5):600-3 [12003599.001]
  • [Cites] Head Neck. 2002 Oct;24(10):921-4 [12369070.001]
  • [Cites] Oncology. 2002;63(4):338-45 [12417788.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):327-33 [12525526.001]
  • [Cites] World J Surg. 2003 Jul;27(7):805-10 [14509511.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Nov;61(11):1289-96 [14613085.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Dec;129(6):713-9 [14663440.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1743-52 [15117998.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 4):3-10 [15124127.001]
  • [Cites] Semin Oncol. 2004 Jun;31(3):382-93 [15190496.001]
  • [Cites] Eur J Surg Oncol. 2004 Sep;30(7):804-6 [15296998.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):365-73 [15380568.001]
  • [Cites] Head Neck. 2004 Oct;26(10):897-902 [15390193.001]
  • [Cites] Head Neck Surg. 1987 Jan-Feb;9(3):157-61 [3623945.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1326-31 [3345488.001]
  • [Cites] Indian J Cancer. 1987 Sep;24(3):167-71 [3450582.001]
  • [Cites] Head Neck. 1989 Mar-Apr;11(2):111-22 [2722487.001]
  • [Cites] Head Neck. 1990 Nov-Dec;12(6):476-82 [2258286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):17-21 [8416876.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1993;250(1):11-7 [8466744.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Sep;119(9):958-63 [8357596.001]
  • [Cites] Indian J Cancer. 1993 Dec;30(4):176-80 [8206500.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):391-4 [7977957.001]
  • [Cites] Br J Oral Maxillofac Surg. 1994 Dec;32(6):347-59 [7848993.001]
  • [Cites] Indian J Cancer. 1994 Dec;31(4):235-9 [7875724.001]
  • [Cites] Br J Oral Maxillofac Surg. 1995 Feb;33(1):3-8 [7718525.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):413-6 [10722019.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):37-46, viii [15649497.001]
  • [Cites] Head Neck. 2005 Jul;27(7):597-602 [15825204.001]
  • [Cites] Head Neck. 2005 Sep;27(9):739-47 [16047368.001]
  • [Cites] Oral Oncol. 2006 Jan;42(1):14-25 [15979381.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Mar;6(3):405-17 [16503857.001]
  • [Cites] Head Neck. 2001 Oct;23(10):907-15 [11592239.001]
  • (PMID = 18701010.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 57
  • [Other-IDs] NLM/ PMC2728300
  •  go-up   go-down


26. Iwabuchi H, Takamori K, Honma H, Asanami S, Tanaka Y: [A case of mandibular gingival cancer T4N0M0 which markedly responded to a combined therapy of nedaplatin with 5-fluorouracil]. Gan To Kagaku Ryoho; 2001 Sep;28(9):1273-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of mandibular gingival cancer T4N0M0 which markedly responded to a combined therapy of nedaplatin with 5-fluorouracil].
  • We recently experienced a case of mandibular gingival cancer T4N0M0 which markedly responded to a combination therapy of nedaplatin (254-S) with 5-fluorouracil (5-FU).
  • Biopsy revealed a moderately differentiated squamous cell carcinoma which extended to the mandible, mandibular gingiva, buccal mucosa, half tongue and oral floor on the left side of the face.
  • As a neoadjuvant chemotherapy (NAC), 254-S at a dose of 100 mg/m2 was intravenously administered on day 1, while 5-FU at a dose of 700 mg/m2/day was intravenously administered from day 1 to 5 in succession.
  • Pathological examination of the extracted tissues showed tumor cells in the tongue only, indicating an excellent effect of this combination therapy of 254-S and 5-FU.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Gingival Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Mandible. Organoplatinum Compounds / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579639.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Yücel A, Cinar C, Aydin Y, Senyuva C, Güzel Z, Cetinkale O, Altintaŝ M: Malignant tumors requiring maxillectomy. J Craniofac Surg; 2000 Sep;11(5):418-29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors requiring maxillectomy.
  • Seventy cases with malignant tumors requiring maxillary resection in the past 10 years were reviewed, retrospectively.
  • The primary site of tumor was adjacent skin in 53%, maxillary sinus or maxilla in 20%, palate and alveolar arch in 13%, lip and buccal mucosa in 13%, and mandible in 1% of the cases.
  • The most common histopathological diagnoses was squamous cell carcinoma (54%), followed by basal cell carcinoma (20%).
  • Postoperative radiotherapy was performed in 32 patients and combined radiotherapy and chemotherapy in 12 patients.
  • Resection of the tumor with free surgical margins and appropriate evaluation of the surgical defect for the most suitable reconstruction are the mainstays of treatment of the midfacial tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Facial Neoplasms / surgery. Female. Humans. Lip Neoplasms / surgery. Male. Mandible / surgery. Mandibular Neoplasms / surgery. Maxillary Neoplasms / surgery. Maxillary Sinus Neoplasms / surgery. Middle Aged. Mouth Neoplasms / surgery. Neck Dissection. Neoplasm Recurrence, Local / surgery. Orbit Evisceration. Palatal Neoplasms / surgery. Palatal Obturators. Radiotherapy, Adjuvant. Retrospective Studies. Skin Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11314064.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Ko SY, Chang KW, Lin SC, Hsu HC, Liu TY: The repressive effect of green tea ingredients on amyloid precursor protein (APP) expression in oral carcinoma cells in vitro and in vivo. Cancer Lett; 2007 Jan 8;245(1-2):81-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The repressive effect of green tea ingredients on amyloid precursor protein (APP) expression in oral carcinoma cells in vitro and in vivo.
  • In a hamster model of N-methyl-N-benzylnitrosamine (MBN)-induced oral carcinogenesis, the incidence of buccal pouch (HBP) carcinomas in MBN-treated hamsters (17.8+/-7.5) was significantly higher than MBN-treated hamsters given tea (10.8+/-3.9) (P<0.05).
  • Furthermore, APP expression and secretion by OECM-1 oral squamous cell carcinoma cells was inhibited by a major polyphenolic ingredient of green tea, (-)-epigallocatechin gallate, in a dose-dependent manner.
  • Thus, APP might promote oral carcinogenesis, whereas green tea ingredients might diminish it by down-regulating APP.
  • [MeSH-major] Amyloid beta-Protein Precursor / genetics. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Plant Preparations / pharmacology. Tea / chemistry
  • [MeSH-minor] Animals. Blotting, Western. Catechin / analogs & derivatives. Catechin / pharmacology. Cell Line, Tumor. Cricetinae. Disease Models, Animal. Dose-Response Relationship, Drug. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Male. Mesocricetus. Mouth Mucosa / drug effects. Mouth Mucosa / metabolism. Mouth Mucosa / pathology. Phytotherapy. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458426.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Plant Preparations; 0 / RNA, Messenger; 0 / Tea; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  •  go-up   go-down


29. Manoharan S, Panjamurthy K, Balakrishnan S, Vasudevan K, Vellaichamy L: Circadian time-dependent chemopreventive potential of withaferin-A in 7,12-dimethylbenz[a]anthracene-induced oral carcinogenesis. Pharmacol Rep; 2009 Jul-Aug;61(4):719-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circadian time-dependent chemopreventive potential of withaferin-A in 7,12-dimethylbenz[a]anthracene-induced oral carcinogenesis.
  • Circadian time-dependent treatment with chemotherapeutic drugs (chronotherapy) optimizes the therapeutic index by maximizing treatment efficacy and minimizing toxicity.
  • The circadian time-dependent chemopreventive and anti-lipid peroxidative efficacy of withaferin-A in 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch carcinogenesis was investigated in the present study.
  • We induced oral squamous cell carcinoma in the buccal pouches of golden Syrian hamsters during the day (4:00, 8:00, 12:00, 16:00, 20:00 and 24:00) by application of DMBA three times per week for 14 weeks.
  • The circadian time-dependent tumor incidence, volume and burden were observed in hamsters treated with either DMBA alone or DMBA + withaferin-A.
  • The circadian pattern of lipid peroxidation by-products, as measured by the formation of thiobarbituric acid reactive substances (TBARS) and enzymatic antioxidants [superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx)], was also analyzed in the buccal mucosa of DMBA-treated hamsters.
  • Oral (po) administration of withaferin-A (20 mg/kg) completely prevented the formation of tumors between 8.00 h and 12.00 h and synchronized the status of lipid peroxidation and antioxidants in the buccal mucosa of hamsters treated with DMBA alone.
  • Also, oral administration of withaferin-A to DMBA-treated animals significantly reduced the formation of tumors and synchronized the status of lipid peroxidation and antioxidants in the rest of the time intervals.
  • Our study thus suggests that withaferin-A has significant chemopreventive and anti-lipid peroxidative potential in DMBA-induced oral carcinogenesis, probably by interfering with DMBA-induced abnormal cell proliferation in the buccal mucosa.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Circadian Rhythm / drug effects. Ergosterol / analogs & derivatives. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cricetinae. Male. Mesocricetus. Phytotherapy / methods. Plant Extracts / administration & dosage. Plant Extracts / isolation & purification. Plant Extracts / therapeutic use. Plant Roots. Withanolides

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. ERGOSTEROL .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815955.001).
  • [ISSN] 1734-1140
  • [Journal-full-title] Pharmacological reports : PR
  • [ISO-abbreviation] Pharmacol Rep
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts; 0 / Withanolides; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; L6DO3QW4K5 / withaferin A; Z30RAY509F / Ergosterol
  •  go-up   go-down


30. Huang AH, Chen YK, Chan AW, Shieh TY, Lin LM: Isolation and characterization of normal hamster buccal pouch stem/stromal cells--a potential oral cancer stem/stem-like cell model. Oral Oncol; 2009 Nov;45(11):e189-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and characterization of normal hamster buccal pouch stem/stromal cells--a potential oral cancer stem/stem-like cell model.
  • The hamster buccal pouch (HBP) is an appropriate experimental model for buccal squamous cell carcinoma (SCC).
  • HBP stem/stromal cells were successfully derived from three of five normal pouch tissues, which differentiated into adipogenic, chondrogenic, and osteogenic lineages, and also expressed stem cell and differentiation markers, indicating their stem cell origin and differentiation capability.
  • In conclusion, normal HBP stem/stromal cells provide a potential avenue for future experimental trials of cancer stem/stem-like cells for treatment of buccal SCC.
  • In vitro, we may detect the sequential changes of normal HBP stem/stromal cells during multistep oral carcinogenesis or the alternations of these cells upon irradiation treatment and/or chemotherapy.
  • [MeSH-major] Antigens, CD / metabolism. Mouth Mucosa / cytology. Stem Cells / cytology. Stromal Cells / cytology
  • [MeSH-minor] Animals. Cheek. Cricetinae. Flow Cytometry. Male. Mesocricetus. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19665423.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


31. Hoebers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, Schellens JH, Stalpers LJ, Bartelink H, Begg AC: Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemother Pharmacol; 2008 May;61(6):1075-81
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
  • PURPOSE: In this study, the formation of cisplatin-DNA adducts after concurrent cisplatin-radiation and the relationship between adduct-formation in primary tumor tissue and normal tissue were investigated.
  • A (32)P-postlabeling technique was used to quantify adducts in normal tissue [white blood cells (WBC) and buccal cells] and tumor.
  • RESULTS: Normal tissue samples for adduct determination were obtained from 63 patients and tumor biopsies from 23 of these patients.
  • Linear relationships and high correlations were observed between the levels of two guanosine- and adenosine-guanosine-adducts in normal and tumor tissue.
  • Adduct levels in tumors were two to five times higher than those in WBC (P<0.001).
  • No significant correlations were found between adduct levels in normal tissues and primary tumor biopsies, nor between WBC and buccal cells.
  • CONCLUSIONS: In concurrent chemoradiotherapy schedules, cisplatin adduct levels in tumors were significantly higher than in normal tissues (WBC).
  • No evidence of a correlation was found between adduct levels in normal tissues and primary tumor biopsies.
  • This lack of correlation may, to some extent, explain the inconsistencies in the literature regarding whether or not cisplatin-DNA adducts can be used as a predictive test in anticancer platinum therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cisplatin / adverse effects. DNA Adducts / drug effects. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / radiotherapy. Humans. Leukocyte Count. Mouth Mucosa / cytology. Predictive Value of Tests

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Jan;79(1):82-8 [10408697.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):750-6 [16550603.001]
  • [Cites] Anal Biochem. 1999 Nov 1;275(1):30-8 [10542106.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • [Cites] Int J Cancer. 2000 Mar 20;89(2):160-6 [10754494.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Lancet. 2001 Sep 8;358(9284):781-6 [11564482.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2992-9 [12231546.001]
  • [Cites] Clin Pharmacol Ther. 2003 May;73(5):417-26 [12732842.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Eur J Cancer Clin Oncol. 1986 Mar;22(3):257-63 [3709595.001]
  • [Cites] Radiother Oncol. 1986 May;6(1):61-74 [3715061.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1986 Nov;50(5):871-84 [3490450.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):3000-4 [3552211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5024-8 [3110781.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):6134-7 [3664513.001]
  • [Cites] Carcinogenesis. 1988 Oct;9(10):1909-11 [2458857.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3556-61 [2340504.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7887-94 [2253228.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2828-32 [2025848.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):612-7 [8499090.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):229-34 [8318875.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5669-75 [8242622.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2843-52 [7514956.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):512-7 [7880732.001]
  • [Cites] Carcinogenesis. 1995 Oct;16(10):2447-53 [7586150.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;37(1-2):23-31 [7497593.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;37(1-2):150-4 [7497585.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1569-75 [8664132.001]
  • [Cites] Int J Cancer. 1996 Nov 15;68(4):452-6 [8945615.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Clin Cancer Res. 1996 Jun;2(6):1063-6 [9816268.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1829-35 [9816137.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1963-71 [16287073.001]
  • (PMID = 17639394.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2270367
  •  go-up   go-down


32. Petruzzi M, De Benedittis M, Pastore L, Pannone G, Grassi FR, Serpico R: Isolated lichen planus of the lip. Int J Immunopathol Pharmacol; 2007 Jul-Sep;20(3):631-5
Hazardous Substances Data Bank. Clobetasol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral lichen planus (OLP) is a relatively common disorder whose cause is still unknown.
  • It occurs mostly on the buccal mucosa, but the gingivae, tongue, floor of the mouth and retromalar pads may also be affected.
  • It rarely occurs on the lips and usually in association with oral lesions.
  • General medical history, examination of the oral cavity and recording of signs and symptoms were carried out for each patient.
  • A complete remission of lesions was observed in eight patients after topical treatment with clobetasol propionate 0.05 percent and tocopherol oil, while partial improvement was noted in those remaining.
  • Isolated LP of the lip is unusual and presents a diagnostic challenge; however an appropriate differential diagnosis is fundamental.
  • Lesions of the lips might represent a more or less precocious phase of oral involvement.
  • Isolated LP of the lip is a well-known condition which responds well to topical treatment with corticosteroids.
  • A thorough medical management and active early treatment are necessary to improve symptoms and might also be a relevant prevention strategy from squamous cell carcinoma risk, although data to fully support this statement still need investigation.
  • [MeSH-major] Lichen Planus, Oral / drug therapy. Lip / drug effects
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Clobetasol / administration & dosage. Clobetasol / therapeutic use. Cohort Studies. Drug Combinations. Female. Humans. Male. Middle Aged. Tocopherols / administration & dosage. Tocopherols / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17880776.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Drug Combinations; 1406-66-2 / Tocopherols; ADN79D536H / Clobetasol
  •  go-up   go-down


33. Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T: A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jun;105(6):783-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer.
  • STUDY DESIGN: This study included 92 patients who were treated by this combination therapy between May 1999 and December 2004.
  • Primary tumor sites included the tongue in 73 patients, base of the tongue in 6 patients, floor of mouth in 4 patients, buccal mucosa in 4 patients, and other sites in 5 patients.
  • In 4 patients, the catheter fell out of the selected artery during treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Radiography, Interventional / methods. Tongue Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206406.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement